What is included with this book?
Samuel Gershon MD, Emeritus Professor of Psychiatry, University of Pittsburgh, PA, USA
List of Contributors | p. xv |
Foreword | p. xix |
Historical Perspectives on Child and Adolescent Psychopharmacology, | p. 1 |
References | p. 4 |
Pharmacoepidemiology of Psychotropic Medications in Youth, | p. 7 |
Introduction | p. 7 |
Prevalence and trends for medications prescribed for ADHD | p. 8 |
Nonstimulant medications for ADHD | p. 11 |
Antidepressant medication | p. 11 |
Antipsychotic medication | p. 13 |
Alpha-agonists | p. 14 |
Anticonvulsant "mood stabilizers" | p. 15 |
Concomitant psychotropic medication | p. 15 |
Preschool psychotropic medication use | p. 17 |
International patterns of psychotropic medication for youth | p. 17 |
Conclusion | p. 18 |
References | p. 18 |
Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry, | p. 25 |
Introduction | p. 25 |
Extent of off-label prescribing | p. 27 |
Need for psychoactive drug treatments for children and adolescents | p. 31 |
Legislation supporting pediatric drug development | p. 33 |
Recommendations to follow when considering off-label prescribing | p. 35 |
References | p. 36 |
The Use of Generic Drugs in Pediatric Psychopharmacology, | p. 39 |
What is a generic drug? | p. 39 |
Why are we discussing generic drugs? | p. 39 |
Basic requirements for generic drugs | p. 40 |
The status of regulations regarding generic drugs and children | p. 41 |
Abbreviated new drug application (ANDA) requirements | p. 42 |
Pediatric assessments of adult drugs (history up to current status) | p. 43 |
Best Pharmaceuticals for Children Act | p. 44 |
Pediatric Research Equity Act | p. 45 |
Intersection of requirements for generics and pediatric assessment | p. 46 |
Future directions | p. 48 |
Concluding thoughts | p. 49 |
References | p. 49 |
Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology, | p. 51 |
Introduction | p. 51 |
Basic concepts in pharmacokinetics | p. 52 |
Dosing considerations for psychoactive drugs in children | p. 55 |
Summary | p. 60 |
References | p. 60 |
Psychostimulants, | p. 65 |
Introduction | p. 65 |
Epidemiology of stimulant use | p. 66 |
Structure and biochemical mechanism of action | p. 66 |
Neuroimaging studies of stimulant effects | p. 67 |
Studies of short-term efficacy | p. 72 |
Studies of long-term efficacy | p. 76 |
Clinical use | p. 79 |
Common side-effects | p. 84 |
Cardiovascular safety issues | p. 86 |
Growth suppression | p. 88 |
Substance use and diversion | p. 88 |
Comparison with nonstimulant treatment | p. 89 |
Treatment of comorbidity | p. 92 |
Pharmacogenetics | p. 93 |
Conclusions | p. 94 |
References | p. 94 |
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders, | p. 105 |
Tricyclic antidepressants (TCAs) | p. 105 |
Drug interactions, contraindications | p. 116 |
Monoamine oxidase inhibitors (MAOIs) | p. 117 |
General summary | p. 122 |
References | p. 123 |
Selective Serotonin Reuptake Inhibitors (SSRIs), | p. 131 |
Pharmacokinetics | p. 131 |
Initiation and titration | p. 133 |
Indications and efficacy | p. 134 |
Adverse effects | p. 146 |
Withdrawal | p. 149 |
References | p. 149 |
Novel (Atypical) Antidepressants, | p. 155 |
Novel (atypical) antidepressants | p. 155 |
General overview | p. 155 |
Bupropion | p. 157 |
Duloxetine | p. 162 |
Mirtazapine | p. 164 |
Trazodone | p. 166 |
Venlafaxine | p. 170 |
Desvenlafaxine | p. 173 |
Alternative treatments | p. 174 |
Summary | p. 175 |
References | p. 176 |
Antipsychotic Agents, | p. 181 |
Introduction | p. 181 |
Chemical properties | p. 182 |
Typical antipsychotics | p. 183 |
Atypical antipsychotics | p. 186 |
Ethical issues: treatment of at-risk populations | p. 212 |
Conclusions | p. 213 |
References | p. 213 |
Lithium, | p. 221 |
Introduction | p. 221 |
Pharmacology | p. 222 |
Potential mechanisms of action | p. 222 |
Evidence for the use of lithium in children and adolescents | p. 232 |
Dosing and drug monitoring | p. 239 |
Contraindications, precautions, and drug interactions | p. 242 |
Side-effects | p. 246 |
References | p. 250 |
Anticonvulsants Used in Child and Adolescent Psychiatric Disorders, | p. 261 |
Introduction | p. 261 |
Divalproex sodium | p. 261 |
Carbamazepine | p. 271 |
Oxcarbazepine | p. 275 |
Lamotrigine | p. 279 |
Gabapentin | p. 284 |
Topiramate | p. 285 |
Conclusion | p. 288 |
References | p. 288 |
Anxiolytics, | p. 301 |
Chemical properties | p. 301 |
Indications | p. 305 |
Contraindications | p. 320 |
Adverse effects | p. 321 |
Overdose | p. 324 |
Abuse/dependence | p. 324 |
Drug interactions | p. 325 |
Available preparations and cost | p. 325 |
Initiation and maintenance of treatment | p. 325 |
Management of specific side-effects | p. 330 |
How to withdraw medication | p. 332 |
References | p. 332 |
Adrenergic Agents in Child and Adolescent Psychiatry, | p. 341 |
Clonidine and guanfacine | p. 341 |
Guanfacine | p. 349 |
Beta-blockers | p. 355 |
Acknowledgements | p. 361 |
References | p. 361 |
Atypical Psychopharmacologic Strategies, | p. 365 |
Opiate antagonists | p. 365 |
Memantine | p. 368 |
Riluzole | p. 369 |
Secretin | p. 371 |
Topiramate | p. 372 |
Herbal medications and dietary supplements | p. 373 |
Ginkgo (Ginkgo biloba) | p. 375 |
Melatonin | p. 381 |
Omega-3 fatty acids | p. 383 |
St. John's wort (Hypericum perforatum) | p. 384 |
Valerian (Valeriana officinalis) | p. 387 |
Conclusion | p. 388 |
References | p. 389 |
Psychopharmacology in Preschool Children, | p. 399 |
Introduction | p. 399 |
Developmental considerations | p. 400 |
Rise in psychopharmacology use | p. 402 |
Psychotherapy before psychopharmacology | p. 403 |
When psychopharmacology may be considered as a first line: pragmatic considerations | p. 404 |
Psychopharmacology in preschool disorders: administration and monitoring | p. 404 |
Off-label prescribing: special considerations | p. 407 |
Use of psychotropics in specific disorders | p. 408 |
Summary | p. 415 |
References | p. 415 |
Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents, | p. 421 |
Bipolar disorder | p. 422 |
Major depressive disorder | p. 429 |
Attention-deficit hyperactivity disorder | p. 431 |
Obsessive-compulsive disorder | p. 433 |
Tics and Tourette's syndrome | p. 434 |
Pervasive developmental disorders | p. 434 |
Conclusion | p. 434 |
References | p. 435 |
Index | p. 439 |
Table of Contents provided by Publisher. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.